Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.

改良型安卡拉痘苗疫苗作为非人灵长类动物模型中预防猴痘性传播的暴露前和暴露后预防的有效性

阅读:6
作者:Herate Cécile, Ferrier-Rembert Audrey, Relouzat Francis, Gallouët Anne-Sophie, Pascal Quentin, Letscher Hélène, Cavarelli Mariangela, Dereuddre-Bosquet Nathalie, Gros Wesley, Delache Benoit, Langlois Sébastien, Timera Hawa, Jarjaval Fanny, Bossevot Laetitia, Ludot Camille, Brua Catherine, Lechemia Maxence, Ferraris Olivier, Silvestre Nathalie, Le Grand Roger, Tournier Jean-Nicolas
The monkeypox virus (MPXV) outbreak of 2022 caused a human disease with unusual epidemiological and clinical features, notably an increase in human-to-human transmission through sexual contact, predominantly among men who have sex with men (MSM). This evolution underscores the need to reassess prevention and control strategies in the context of a sexually transmitted disease. Here, we show that rectal challenge of male cynomolgus macaques with a 2022 clade IIb MPXV isolate mimics sexual transmission, leading to rectal infection, with systemic and male genital tract dissemination and seminal fluid shedding. Vaccination with modified-vaccinia Ankara (MVA) protected the macaques from subsequent rectal MPXV challenge. However, MVA failed to prevent the disease when administered four days post-exposure to MPXV. These findings have a critical impact on outbreak management and highlight the importance of reevaluating MVA post-exposure prophylaxis protocols.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。